93Z Stock Chart & Stats
€4.08
€0.00(0.00%)
At close: 4:00 PM EST
€4.08
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.54 - €20.53
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
€10.35M
Enterprise Value€45.78
Total Cash (Recent Filing)€911.50K
Total Debt (Recent Filing)€29.09M
Price to Earnings (P/E)0.5
Beta0.27
Next Earnings
Apr 21, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.20
Shares Outstanding2,299,925
10 Day Avg. Volume1
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
93Z FAQ
What was Marinomed Biotech AG’s price range in the past 12 months?
Marinomed Biotech AG lowest stock price was €3.54 and its highest was €20.53 in the past 12 months.
What is Marinomed Biotech AG’s market cap?
Marinomed Biotech AG’s market cap is €10.35M.
When is Marinomed Biotech AG’s upcoming earnings report date?
Marinomed Biotech AG’s upcoming earnings report date is Apr 21, 2027 which is in 215 days.
How were Marinomed Biotech AG’s earnings last quarter?
Marinomed Biotech AG released its earnings results on Apr 22, 2026. The company reported -€1.463 earnings per share for the quarter.
Is Marinomed Biotech AG overvalued?
According to Wall Street analysts Marinomed Biotech AG’s price is currently Overvalued.
Does Marinomed Biotech AG pay dividends?
Marinomed Biotech AG does not currently pay dividends.
What is Marinomed Biotech AG’s EPS estimate?
Marinomed Biotech AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marinomed Biotech AG have?
Marinomed Biotech AG has 2,299,925 shares outstanding.
What happened to Marinomed Biotech AG’s price movement after its last earnings report?
Marinomed Biotech AG reported an EPS of -€1.463 in its last earnings report. Following the earnings report the stock price went down -0.922%.
Which hedge fund is a major shareholder of Marinomed Biotech AG?
Currently, no hedge funds are holding shares in DE:93Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marinomed Biotech AG
Marinomed Biotech AG is an Austrian-based biopharmaceutical firm dedicated to developing therapeutic solutions for viral and immunological conditions, with its market presence spanning across Austria, other European nations, and globally. Their comprehensive product pipeline includes Budesolv, which addresses allergic rhinitis and autoimmune gastritis, and Tacrosolv, currently undergoing Phase II clinical trials for anterior inflammatory eye diseases. Also featured in their development are Carravin, designed to alleviate nasal congestion, and Inhaleen, which is in Phase I clinical evaluation for viral pneumonia. Additionally, the company offers Carragelose, a range of products like nasal and throat sprays and lozenges, all formulated to combat viral respiratory infections. Established in 2006, the company was initially named Marinomed Biotechnologie GmbH, adopting its current name, Marinomed Biotech AG, in June 2017, and is headquartered in Korneuburg, Austria.